Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659475 · ClinicalTrials.gov registry record · Phase 2
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
A Phase 2 study, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02659475 is a Phase 2 study that has completed, run by Lindner Center of HOPE. The registered enrollment target is 10 participants.
The verdict
NCT02659475, a Phase 2 study, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this project is to evaluate the effectiveness and tolerability of the novel weight management medication PHEN/TPM ER (Qsymia®)along with nutritional and lifestyle modification counseling in the treatment of binge eating disorder (BED) in overweight or obese individuals.
Interventions
- DRUG PHEN/TPM ER (Qsymia®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659475
The ClinicalTrials.gov registry entry for NCT02659475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PHEN/TPM ER (Qsymia®) is the first listed.
NCT02659475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659475 about?
NCT02659475 is a clinical study titled "Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)". The goal of this project is to evaluate the effectiveness and tolerability of the novel weight management medication PHEN/TPM ER (Qsymia®)along with nutritional and lifestyle modification counseling in the treatment of binge eating disorder (BED) in overweight or obese individuals.
What is the current status of trial NCT02659475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02659475?
The interventions under investigation include: PHEN/TPM ER (Qsymia®) (DRUG).
Who is sponsoring clinical trial NCT02659475?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.